IP Library Granted Patent US 8,907,157
Granted Patent B2
US 8,907,157 · App. 12/701,464 · Granted Dec 9, 2014

Methods for producing transgenic rodents having recombinant immunoglobulin loci

Inventor: Roland Buelow (Palo Alto, CA)
Assignee: OMT, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,907,157
App. No.
12/701,464
Granted
Dec 9, 2014
Kind
B2
Abstract

The invention provides methods for the production of transgenic animals comprising a recombinant Ig locus, as well as transgenic antibodies derived therefrom. The methods involve meganuclease cleavage-stimulated homologous recombination in mammalian embryos.

Claims (12)

1. A method for integrating an exogenous nucleic acid sequence into an endogenous immunoglobulin (Ig) gene of a rodent embryo, comprising

introducing a meganuclease into said rodent embryo, wherein said meganuclease causes a chromosomal break in genomic DNA of said embryo at a cleavage site located within 1.5 kb of said Ig gene, and

introducing into said rodent embryo an exogenous nucleic acid sequence, wherein said exogenous nucleic acid sequence comprises an insertion sequence flanked by two homology arms such that said insertion sequence is integrated into said genomic DNA at said endogenous Ig gene by homologous recombination.

2. The method according to claim 1 , wherein said rodent embryo is a single cell fertilized oocyte.

3. The method according to claim 1 , wherein said insertion sequence is homologous to an exon of said endogenous Ig gene.

4. The method according to claim 3 , wherein said insertion sequence comprises a human Ig exon.

5. The method according to claim 3 , wherein said endogenous Ig gene comprises an Ig gene segment selected from the group consisting of a rodent variable (V) gene segment, a rodent diversity (D) gene segment, a rodent joining (J) gene segment, and a rodent constant (C) gene segment.

6. The method according to claim 1 , wherein said insertion sequence comprises a nucleotide sequence selected from the group consisting of a human variable (V) Ig segment, a human diversity (D) Ig segment, a human joining (J) Ig segment, a human constant (C) Ig segment, and portions thereof.

7. The method according to claim 6 , wherein said insertion sequence comprises a human V gene segment.

8. The method according to claim 1 , wherein said insertion sequence introduces a deletion into said endogenous Ig gene.

9. The method according to claim 1 , wherein said insertion sequence introduces a stop codon into said endogenous Ig gene.

10. The method according to claim 1 , wherein said insertion sequence disrupts said endogenous Ig gene.

Assignments (4)
CHANGE OF NAME Recorded Nov 16, 2022
From: OMNIAB, INC.
To: OMNIAB OPERATIONS, INC.
Reel/Frame 061953/0063 →
CHANGE OF NAME Recorded Mar 17, 2022
From: OPEN MONOCLONAL TECHNOLOGY, INC.
To: OMNIAB, INC.
Reel/Frame 059435/0056 →
CORRECTIVE ASSIGNMENT TO CORRECT THE RECEIVING PARTY'S NAME PREVIOUSLY RECORDED AT REEL: 037830 FRAME: 0484. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 18, 2016
From: BUELOW, ROLAND, PH.D
To: OPEN MONOCLONAL TECHNOLOGY, INC.
Reel/Frame 040648/0034 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 25, 2016
From: BUELOW, PH.D., ROLAND
To: OMT, INC.
Reel/Frame 037830/0484 →
Continuity (4)
Continuation In Part 12130818 · May 30, 2008
Provisional Application 60941619 · Jun 1, 2007
Provisional Application 61044324 · Apr 11, 2008
Related Publication 20100212035A1 · Aug 19, 2010